GENEVA, SWITZERLAND -- (MARKET WIRE) -- May 25, 2007 -- Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) a biopharmaceutical company, announces that in vivo preclinical data presented in a poster at the 8e Colloque de la Societe des Neurosciences meeting, Montpellier, France, May 22, 2007 showed that ANAVEX 1-41 and ANAVEX 2-73 -new potent muscarinic ligands with a high affinity for the sigma-1 receptor- suggest a possibly important neuroprotective and anti-amnesic efficacy in Alzheimer’s Disease (AD).
